Arixa Pharmaceuticals

About Arixa Pharmaceuticals

In the world of pharmaceuticals, the race for the next blockbuster drug often involves massive labs and huge teams. But Arixa Pharmaceuticals took a different path. Founded in 2016 by medicinal chemist Dr. Eric M. Gordon and venture capitalist Dr. John Freund, the company was built on a lean, virtual model. It had no full-time employees or physical overhead, instead using a network of contractors and consultants. The company focused on a critical problem: the rise of drug-resistant Gram-negative bacteria. Many powerful antibiotics for these infections could only be administered intravenously in a hospital. Arixa’s core innovation was developing a way to make these drugs available in an oral pill form. Their lead candidate, ARX-1796, was a prodrug of avibactam, an existing FDA-approved intravenous-only inhibitor that helps antibiotics fight resistant bacteria. Arixa’s chemistry allowed for high absorption when taken orally, a significant breakthrough. This novel approach caught the attention of a major player. In October 2020, Pfizer’s Hospital Business announced it would acquire Arixa Pharmaceuticals. While the financial terms were not disclosed, the deal validated Arixa’s strategy. Pfizer gained a promising drug candidate that could potentially become the first new oral beta-lactamase inhibitor combination in over 35 years, allowing patients to avoid hospital stays.